-transparent.png){kind=logo}
Epirubicin was studied in a phase I setting to find the maximum tolerated dose when given weekly for 3 of 4 weeks. Forty-one evaluable patients were treated in groups at doses increasing from 20 to 45 mg/m2. The highest dose level produced the maximum degree of myelosuppression (lowest neutrophil count, 1.9 X 10(9)/L; range, 0-3.7) recorded on Day 22. This was well-tolerated in this group of mainly pretreated patients. Nonhematologic side effects were minimal. This dose schedule allows a greater dose per unit time to be administered than other recommended schedules for epirubicin.
Related Publications
R Snyder, and
J Bishop, and
G Brodie, and
W Burns, and
A Coates, and
J Levi, and
D Raghavan, and
M Schwarz, and
M Tattersall, and
D Thomson
January 1986,
Investigational new drugs,
R Snyder, and
J Bishop, and
G Brodie, and
W Burns, and
A Coates, and
J Levi, and
D Raghavan, and
M Schwarz, and
M Tattersall, and
D Thomson
July 1992,
Gan to kagaku ryoho. Cancer & chemotherapy,
R Snyder, and
J Bishop, and
G Brodie, and
W Burns, and
A Coates, and
J Levi, and
D Raghavan, and
M Schwarz, and
M Tattersall, and
D Thomson
January 1981,
Cancer treatment reports,
R Snyder, and
J Bishop, and
G Brodie, and
W Burns, and
A Coates, and
J Levi, and
D Raghavan, and
M Schwarz, and
M Tattersall, and
D Thomson
September 2007,
Annals of oncology : official journal of the European Society for Medical Oncology,
R Snyder, and
J Bishop, and
G Brodie, and
W Burns, and
A Coates, and
J Levi, and
D Raghavan, and
M Schwarz, and
M Tattersall, and
D Thomson
March 1999,
British journal of cancer,
R Snyder, and
J Bishop, and
G Brodie, and
W Burns, and
A Coates, and
J Levi, and
D Raghavan, and
M Schwarz, and
M Tattersall, and
D Thomson
October 1983,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
R Snyder, and
J Bishop, and
G Brodie, and
W Burns, and
A Coates, and
J Levi, and
D Raghavan, and
M Schwarz, and
M Tattersall, and
D Thomson
May 1986,
Cancer treatment reports,
R Snyder, and
J Bishop, and
G Brodie, and
W Burns, and
A Coates, and
J Levi, and
D Raghavan, and
M Schwarz, and
M Tattersall, and
D Thomson
February 1990,
Investigational new drugs,
R Snyder, and
J Bishop, and
G Brodie, and
W Burns, and
A Coates, and
J Levi, and
D Raghavan, and
M Schwarz, and
M Tattersall, and
D Thomson
January 1993,
European journal of cancer (Oxford, England : 1990),
R Snyder, and
J Bishop, and
G Brodie, and
W Burns, and
A Coates, and
J Levi, and
D Raghavan, and
M Schwarz, and
M Tattersall, and
D Thomson
September 1980,
Cancer,
